D
Deedra Nicolet
Researcher at Ohio State University
Publications - 84
Citations - 3382
Deedra Nicolet is an academic researcher from Ohio State University. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 25, co-authored 69 publications receiving 2688 citations. Previous affiliations of Deedra Nicolet include Case Western Reserve University & University of Maryland, Baltimore.
Papers
More filters
Journal ArticleDOI
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
Krzysztof Mrózek,Guido Marcucci,Deedra Nicolet,Kati Maharry,Heiko Becker,Susan P. Whitman,Klaus H. Metzeler,Sebastian Schwind,Yue-Zhong Wu,Jessica Kohlschmidt,Mark J. Pettenati,Nyla A. Heerema,AnneMarie W. Block,Shivanand R. Patil,Maria R. Baer,Jonathan E. Kolitz,Joseph O. Moore,Andrew J. Carroll,Richard Stone,Richard A. Larson,Clara D. Bloomfield +20 more
TL;DR: The ELN classification clearly separates the genetic groups by outcome, supporting its use for risk stratification in clinical trials.
Journal ArticleDOI
Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics
Gi Bang Koo,Michael J. Morgan,Da Gyum Lee,Woo-Jung Kim,Jung Ho Yoon,Ja Seung Koo,Seung Il Kim,Soo Jung Kim,Mi Kwon Son,Soon-Sun Hong,Jean M. Mulcahy Levy,Daniel A. Pollyea,Craig T. Jordan,Pearlly S. Yan,David Frankhouser,Deedra Nicolet,Kati Maharry,Guido Marcucci,Kyeong Sook Choi,Hyeseong Cho,Andrew Thorburn,You-Sun Kim +21 more
TL;DR: This work shows that programmed necrosis is activated in response to many chemotherapeutic agents and contributes to chemotherapy-induced cell death, and proposes that RIP3-deficient cancer patients may benefit from receiving hypomethylating agents to induce RIP3 expression prior to treatment with conventional Chemotherapeutics.
Journal ArticleDOI
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H. Metzeler,Heiko Becker,Kati Maharry,Kati Maharry,Michael D. Radmacher,Michael D. Radmacher,Jessica Kohlschmidt,Jessica Kohlschmidt,Krzysztof Mrózek,Deedra Nicolet,Deedra Nicolet,Susan P. Whitman,Yue-Zhong Wu,Sebastian Schwind,Bayard L. Powell,Thomas H. Carter,Meir Wetzler,Joseph O. Moore,Jonathan E. Kolitz,Maria R. Baer,Andrew J. Carroll,Richard A. Larson,Michael A. Caligiuri,Guido Marcucci,Clara D. Bloomfield +24 more
TL;DR: This first study of ASXL1 mutations in primary CN-AML demonstrates that AS XL1-mutated older patients, particularly within the ELN Favorable group, have unfavorable outcomes and may be candidates for experimental treatment approaches.
Journal ArticleDOI
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures
Jason H. Mendler,Kati Maharry,Michael D. Radmacher,Krzysztof Mrózek,Heiko Becker,Klaus H. Metzeler,Sebastian Schwind,Susan P. Whitman,Jihane Khalife,Jessica Kohlschmidt,Deedra Nicolet,Bayard L. Powell,Thomas H. Carter,Meir Wetzler,Joseph O. Moore,Jonathan E. Kolitz,Maria R. Baer,Andrew J. Carroll,Richard A. Larson,Michael A. Caligiuri,Guido Marcucci,Clara D. Bloomfield +21 more
TL;DR: RUNX1 mutations are twice as common in older than younger patients with CN-AML and negatively impact outcome in both age groups, potentially leading to novel therapeutic approaches.
Journal ArticleDOI
Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia
Guido Marcucci,Klaus H. Metzeler,Sebastian Schwind,Heiko Becker,Kati Maharry,Krzysztof Mrózek,Michael D. Radmacher,Jessica Kohlschmidt,Deedra Nicolet,Susan P. Whitman,Yue-Zhong Wu,Bayard L. Powell,Thomas H. Carter,Jonathan E. Kolitz,Meir Wetzler,Andrew J. Carroll,Maria R. Baer,Joseph O. Moore,Michael A. Caligiuri,Richard A. Larson,Clara D. Bloomfield +20 more
TL;DR: DNMT3A-R882 mutations are associated with adverse prognosis in older patients, and non-R886-DNMT 3A mutations areassociated with adverse prediction in younger patients, according to multivariable analyses.